Finepoint Capital LP Apellis Pharmaceuticals, Inc. Transaction History

Finepoint Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$76.68 - $93.31 $3.22 Million - $3.92 Million	-42,000 Reduced 14.8%	241,690 $22 Million
Q1 2023 May 12, 2023	SELL	$46.59 - $66.96 $2.39 Million - $3.43 Million	-51,200 Reduced 15.29%	283,690 $18.7 Million
Q4 2022 Feb 13, 2023	BUY	$43.24 - $61.04 $2.97 Million - $4.2 Million	68,800 Added 25.86%	334,890 $17.3 Million
Q3 2022 Nov 10, 2022	SELL	$44.76 - $69.66 $2.34 Million - $3.64 Million	-52,310 Reduced 16.43%	266,090 $18.2 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $11.2 Million - $18.9 Million	318,400 New	318,400 $14.4 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

Stay updated on Finepoint Capital LP with notifications on news.